| scholarly article | Q13442814 |
| P50 | author | Eric O Freed | Q67208349 |
| P2093 | author name string | Ken Fujii | |
| Phuong Pham | |||
| Rachel Van Duyne | |||
| Lillian S Kuo | |||
| P2860 | cites work | The role of cell-to-cell transmission in HIV infection | Q72188964 |
| Avoiding the void: cell-to-cell spread of human viruses | Q22251022 | ||
| Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy | Q22251085 | ||
| Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding | Q24291784 | ||
| The Protein Network of HIV Budding | Q24294993 | ||
| Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins | Q24296475 | ||
| Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding | Q24299705 | ||
| Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function | Q24530772 | ||
| Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release | Q24563651 | ||
| Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag) | Q24633537 | ||
| Virus budding and the ESCRT pathway | Q26828590 | ||
| Structural basis for viral late-domain binding to Alix | Q27643742 | ||
| Structural and functional studies of ALIX interactions with YPX(n)L late domains of HIV-1 and EIAV | Q27649242 | ||
| HIV Cell-to-Cell Spread Results in Earlier Onset of Viral Gene Expression by Multiple Infections per Cell | Q27681313 | ||
| Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G | Q27704710 | ||
| AIP1/ALIX Is a Binding Partner for HIV-1 p6 and EIAV p9 Functioning in Virus Budding | Q28204548 | ||
| HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress | Q28207991 | ||
| Dolutegravir monotherapy of simian immunodeficiency virus-infected macaques selects for several patterns of resistance mutations with variable virological outcomes | Q58089545 | ||
| Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein | Q28646759 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Human immunodeficiency virus reverse transcriptase and protease sequence database | Q29616403 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. | Q29622903 | ||
| Multiploid inheritance of HIV-1 during cell-to-cell infection | Q30501773 | ||
| Antiretroviral agents effectively block HIV replication after cell-to-cell transfer | Q30524224 | ||
| Human immunodeficiency virus type 1 inhibits DNA damage-triggered apoptosis by a Nef-independent mechanism | Q33755059 | ||
| Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase | Q33782016 | ||
| Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle | Q33782781 | ||
| Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41. | Q33787186 | ||
| Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions | Q33789251 | ||
| The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner | Q34104639 | ||
| p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease | Q34288376 | ||
| Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells | Q34291056 | ||
| Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency | Q34303589 | ||
| Directed egress of animal viruses promotes cell-to-cell spread | Q34327423 | ||
| Phenotypic properties of transmitted founder HIV-1 | Q34336058 | ||
| Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial | Q34373867 | ||
| Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. | Q34544718 | ||
| HIV-1 mutates to evade IFITM1 restriction. | Q34761788 | ||
| Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission | Q35105679 | ||
| Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. | Q35237575 | ||
| Syncytial apoptosis signaling network induced by the HIV-1 envelope glycoprotein complex: an overview. | Q36022247 | ||
| IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein. | Q36150469 | ||
| Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). | Q36447469 | ||
| Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. | Q36524357 | ||
| Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. | Q36632356 | ||
| A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity | Q36756570 | ||
| Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity | Q36944098 | ||
| The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions | Q37152680 | ||
| Functional role of Alix in HIV-1 replication | Q37349062 | ||
| Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells | Q37425205 | ||
| Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus | Q37546388 | ||
| Mutations in the feline immunodeficiency virus envelope glycoprotein confer resistance to a dominant-negative fragment of Tsg101 by enhancing infectivity and cell-to-cell virus transmission | Q37619606 | ||
| Recent trends in HIV-1 drug resistance | Q37657560 | ||
| Virus cell-to-cell transmission. | Q37726587 | ||
| Host factors involved in retroviral budding and release. | Q37890247 | ||
| Cell-to-Cell Spread of Retroviruses | Q37945208 | ||
| HIV-1 assembly, budding, and maturation | Q38023864 | ||
| Viral precursor polyproteins: keys of regulation from replication to maturation | Q38100451 | ||
| HIV integrase inhibitors: 20-year landmark and challenges | Q38124090 | ||
| Will drug resistance against dolutegravir in initial therapy ever occur? | Q38478832 | ||
| HIV-1 assembly, release and maturation. | Q38539565 | ||
| Combination antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human immunodeficiency virus-1. | Q38718627 | ||
| Cell-to-Cell Spread of HIV and Viral Pathogenesis. | Q38816960 | ||
| Impact of HIV-1 infection pathways on susceptibility to antiviral drugs and on virus spread | Q38851814 | ||
| Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines | Q38950134 | ||
| Different Pathways Leading to Integrase Inhibitors Resistance | Q39103603 | ||
| HIV drug resistance against strand transfer integrase inhibitors | Q39352571 | ||
| HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike | Q39365785 | ||
| Growing functions of the ESCRT machinery in cell biology and viral replication. | Q39376804 | ||
| A Consensus View of ESCRT-Mediated Human Immunodeficiency Virus Type 1 Abscission. | Q39439244 | ||
| An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus | Q39597595 | ||
| Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike | Q40125807 | ||
| Emergent drug resistance with integrase strand transfer inhibitor-based regimens | Q40265270 | ||
| JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1. | Q40331435 | ||
| Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors | Q40399853 | ||
| Generation of high-titer pseudotyped retroviral vectors with very broad host range | Q40571115 | ||
| Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail | Q40579232 | ||
| Role of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits | Q40638638 | ||
| HIV-1 evolves into a nonsyncytium-inducing virus upon prolonged culture in vitro. | Q40920580 | ||
| Improved envelope function selected by long-term cultivation of a translation-impaired HIV-1 mutant | Q41040160 | ||
| A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects | Q41484730 | ||
| Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO | Q41664122 | ||
| Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors | Q41676212 | ||
| Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens | Q41714015 | ||
| Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update | Q41926589 | ||
| The interferon-inducible MxB protein inhibits HIV-1 infection. | Q42267969 | ||
| Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study | Q42285688 | ||
| Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies | Q43095098 | ||
| Drug resistance in patients experiencing early virological failure under a triple combination including indinavir | Q43730540 | ||
| Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity | Q43894349 | ||
| Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage | Q45229513 | ||
| Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations | Q47551889 | ||
| The S230R Integrase Substitution Associated with Viral Rebound during DTG Monotherapy Confers Low Levels INSTI Drug Resistance. | Q52721657 | ||
| An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. | Q53583835 | ||
| HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G. | Q55033661 | ||
| HIV-1 cell-to-cell transmission and broadly neutralizing antibodies | Q57030223 | ||
| No Evidence for Evolution of Protease Inhibitor Resistance from Standard Genotyping, After Three Years of Treatment with Darunavir/Ritonavir, With or Without Nucleoside Analogues | Q58000783 | ||
| P433 | issue | 18 | |
| P304 | page(s) | 9040-9049 | |
| P577 | publication date | 2019-04-11 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle | |
| P478 | volume | 116 |
| Q91680140 | A systematic review of the genetic mechanisms of dolutegravir resistance |
| Q99557057 | Elucidating the basis for permissivity of the MT-4 T-cell line to replication of an HIV-1 mutant lacking the gp41 cytoplasmic tail |
| Q92992903 | Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition |
Search more.